Skip to main content
Clinical Trials/NCT06179498
NCT06179498
Recruiting
N/A

A Randomized Trial to Test the Efficacy of a Partner Navigation Intervention for HCV Treatment Among Young Adult People Who Inject Drugs

University of California, San Francisco1 site in 1 country500 target enrollmentMarch 25, 2024
ConditionsHepatitis C

Overview

Phase
N/A
Intervention
Not specified
Conditions
Hepatitis C
Sponsor
University of California, San Francisco
Enrollment
500
Locations
1
Primary Endpoint
Intervention efficacy
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The Partner Navigation Intervention Study is a randomized controlled study (RCT) to assess the efficacy and mechanism of action of the first behavioral intervention to increase hepatitis C (HCV) treatment initiation among adult people who inject drugs (PWID).

Detailed Description

After an initial ramp-up phase to ensure intervention materials and protocols meet the needs of the target population and organizational setting, we will apply a stratified randomized design to enroll 250 adult PWID with recently diagnosed HCV infection ("index") and their primary injecting partner("partner") into a randomized control efficacy trial of a two-session partner navigation intervention, compared to standard of care. The primary endpoint is starting HCV treatment. Recruitment will over sample PWID between 18-30 years of age.

Registry
clinicaltrials.gov
Start Date
March 25, 2024
End Date
June 1, 2027
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Self report injecting drugs in the past month
  • Self report a primary injecting partner (currently inject drugs together)
  • HCV infection identified at partnering community-based clinical site

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Intervention efficacy

Time Frame: 6 months, 12 months, and 24 months after HCV infection disclosure visit.

Assessed by comparing the proportion of those enrolled in the intervention group who initiated treatment to the proportion of those enrolled in the control group who initiated treatment at 6 months, 12 months, and 24 months after HCV infection disclosure visit.

Secondary Outcomes

  • HCV Treatment Completion(Point of HCV treatment initiation up to 3 years)
  • Change in Partner Support (Intervention mechanism)(1 week, 1 month, 3 months and 6-months after HCV infection disclosure visit)
  • Sustained Virologic Response at 12 weeks post treatment completion (SVR12)(Point of HCV treatment initiation up to 3 years)

Study Sites (1)

Loading locations...

Similar Trials